StockData
Kailera Therapeutics, Inc. logo

Kailera Therapeutics, Inc. (KLRA) stock

KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026
$11.79−0.41 (-3.36%)

Close on Nov 18, 2026Market cap $1.53BP/E –Yield –

Kailera Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$106.34M–
Q2 FY2026Jun 30, 2026-$121.37M–
Q1 FY2026Mar 31, 2026-$84.66M–
Q3 FY2025Sep 30, 2025-$40.11M–
Q2 FY2025Jun 30, 2025-$30.65M–
Q1 FY2025Mar 31, 2025-$20.46M–

More Kailera Therapeutics figures

See a number that looks wrong?